Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIV-1 Seropositive”

26 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 26 results

Not applicableStudy completedNCT00002443
What this trial is testing

The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Who this might be right for
HIV Infections
Merck Sharp & Dohme LLC 780
Early research (Phase 1)Study completedNCT00000642
What this trial is testing

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns

Who this might be right for
HIV InfectionsPregnancy
National Institute of Allergy and Infectious Diseases (NIAID) 30
Early research (Phase 1)Study completedNCT00917813
What this trial is testing

Anti-HIV Monoclonal Antibody KD-247

Who this might be right for
HIV Infections
The Chemo-Sero-Therapeutic Research Institute 27
Post-approval studies (Phase 4)Study completedNCT00002179
What this trial is testing

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Who this might be right for
HIV Infections
Merck Sharp & Dohme LLC 200
Not applicableStudy completedNCT03957369
What this trial is testing

Primary Resistance in HIV Patients in Colombia

Who this might be right for
HIV Infection
Fundacion REVIVA, Red de VIH del Valle del Cauca 527
Early research (Phase 1)Study completedNCT00384787
What this trial is testing

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 90
Early research (Phase 1)Study completedNCT02568332
What this trial is testing

Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

Who this might be right for
Hepatitis C Infection
University of Oxford 20
Not applicableWithdrawnNCT01059084
What this trial is testing

An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons

Who this might be right for
HIVHIV Infections
University of Washington
Testing effectiveness (Phase 2)Study completedNCT00541463
What this trial is testing

Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

Who this might be right for
HIV Infections
Merck Sharp & Dohme LLC 330
Not applicableStudy completedNCT02116374
What this trial is testing

Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients

Who this might be right for
HIV-1 Infection
ANRS, Emerging Infectious Diseases 80
Not applicableStudy completedNCT00006443
What this trial is testing

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 24
Early research (Phase 1)Study completedNCT00114699
What this trial is testing

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

Who this might be right for
HIV Infections
Human Genome Sciences Inc. 40
Early research (Phase 1)Study completedNCT00002363
What this trial is testing

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

Who this might be right for
HIV Infections
Columbia Research Laboratories 20
Not applicableStudy completedNCT00002375
What this trial is testing

Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

Who this might be right for
HIV Infections
Merck Sharp & Dohme LLC 24
Early research (Phase 1)Study completedNCT00002353
What this trial is testing

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

Who this might be right for
HIV Infections
United Biomedical
Not applicableStudy completedNCT00990678
What this trial is testing

Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

Who this might be right for
HIV Seropositive
Hvidovre University Hospital 60
Not applicableStudy completedNCT01143519
What this trial is testing

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Who this might be right for
HIV-1 SeropositiveInflammationCancer+1 more
National Institute of Environmental Health Sciences (NIEHS) 178
Early research (Phase 1)Study completedNCT00000667
What this trial is testing

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 20
Not applicableStudy completedNCT00002155
What this trial is testing

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

Who this might be right for
HIV Infections
Merck Sharp & Dohme LLC 600
Early research (Phase 1)Study completedNCT00000633
What this trial is testing

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 55
Next Page